Methotrexate: 5 agencies, 2009–2026
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
The file has been open for more than a decade: 16.8 years separate the first record, 12 Oct 2009 at SMC (Scotland), from the most recent, 21 Jul 2026 at CONITEC (Brazil).
PBAC (Australia) changed its position: not recommended in 2016, recommended by 2024, after a resubmission.
No assessment is on file from PHARMAC (New Zealand), AWMSG (Wales), CIPM (Spain) and G-BA (Germany), each among the eight highest-volume agencies here.
Not every gap is a refusal: for methotrexate, 1 was withdrawn or terminated before a decision — an outcome set by the company rather than the assessor.
The file is active: 7 of 38 records date from 2023 or later.
5 distinct indication wordings are recorded for methotrexate by the agencies that label one in English (PBAC and SMC).
5 of these 38 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
SMC (Scotland) was first to assess methotrexate, on 12 Oct 2009; TLV (Sweden) did not open a file until 28 Jun 2022 — an unusually long tail of 12.7 years between the earliest and latest system to look at it.
The record arrives in waves: 10 separate years each carry two or more decisions, spread across 14 years in total.
4 of the 5 agencies here assessed methotrexate more than once, HAS (France) most often at 27 entries — repeat review is the norm for this molecule rather than the exception.
Coverage is narrow: only 5 of the 18 agencies here have assessed methotrexate.
The full ledger for methotrexate reads 28 recommended, 6 other, 2 restricted and 1 withdrawn, with 1 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| CONITEC (Brazil) | 27 May 2025 | Tratamento de pacientes com dermatite atópica moderada a grave. | incorporated into SUS | source |
| TLV (Sweden) | 16 Jun 2023 | Jylamvo ingår i högkostnadsskyddet med begränsning för ytterligare en patientgrupp | restricted subsidy | source |
| HAS (France) | 5 Oct 2016 | Listing (Transparency Committee) | ASMR V | source |
| PBAC (Australia) | 2016 | Rheumatoid arthritis or psoriasis | The PBAC did not recommend the PBS listing of methotrexate pre-filled syringe for the trea… | source |
| SMC (Scotland) | 12 Oct 2009 | Severe recalcitrant disabling psoriasis | accepted | source |
33 further decisions for methotrexate, across 4 agencies, are not shown here. They include the most recent record on file, 21 Jul 2026 from CONITEC (Brazil); its outcome is in the subscriber dataset. They link to 16 further source documents.
Related molecules
- adalimumab — same ATC class L04A — Immunosuppressants
- upadacitinib — same ATC class L04A — Immunosuppressants
- secukinumab — same ATC class L04A — Immunosuppressants
- tocilizumab — same ATC class L04A — Immunosuppressants
- ustekinumab — same ATC class L04A — Immunosuppressants
- infliximab — same ATC class L04A — Immunosuppressants
Coverage: 38 decisions for methotrexate from 5 agencies, 2009 to 2026. Data to 7 Sep 2026. ATC class L04A — Immunosuppressants. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.